{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-086685","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.417045+00:00","generated_at":"2026-05-17T08:31:40.922766+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Palvella posts updated corporate presentation; no material new disclosures","bullets":["Filed an 8-K under Item 7.01 furnishing a corporate presentation dated September 2025.","Presentation describes first-in-disease therapies for rare genetic skin diseases.","No financial results, pipeline updates, or guidance changes disclosed in the filing.","Presentation will be used in investor meetings going forward."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-086685","json":"https://secwatch.observer/filing/0001104659-25-086685.json","markdown":"https://secwatch.observer/filing/0001104659-25-086685.md","text":"https://secwatch.observer/filing/0001104659-25-086685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000110465925086685/0001104659-25-086685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000110465925086685/tm2525080d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:31:40.922766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}